Table 4.
Postoperative outcomes
| References | Author | DOAC/Warfarin | 30‐Day Thromboembolic (events/Interruptions, %) | 30‐Day major bleeding (Events/Interruptions, %) | 30‐day Minor Bleeding (events/Interruptions, %) | 30‐Day Overall Mortality (events/Interruptions, %) |
|---|---|---|---|---|---|---|
| 20 | Healey |
Dabigatran Warfarin |
14/3033 (0.46) 7/1558 (0.45) |
135/3033 (4.45) 72/1558 (4.62) |
259/3033 (8.54) 122/1558 (7.83) |
– |
| 21 | Sherwood |
Rivaroxaban Warfarin |
4/1297 (0.31) 8/1683 (0.48) |
14/1297 (1.08) 18/1683 (1.07) |
20/1297 (1.54) 24/1683 (1.43) |
1/1297 (0.08) 3/1683 (0.18) |
| 22 | Garcia |
Apixaban Warfarin |
9/2877 (0.31) 10/2864 (0.35) |
46/2792 (1.65) 35/2774 (1.26) |
26/2792 (0.93) 26/2774 (0.94) |
30/2877 (1.04) 15/2864 (0.52) |
| 23 | Douketis |
Edoxaban Warfarin |
10/2053 (0.49) 6/1063 (0.56) |
23/2053 (1.12) 11/1063 (1.03) |
56/2053 (2.73) 30/1063 (2.82) |
22/2053 (1.07) 13/1063 (1.22) |
| 24 | Schulman | Dabigatran | 1/531 (0.19) | 10/531 (1.88) | 24/531 (4.52) | 4/531 (0.75) |
| 25 | Kosiuk | Dabigatran | 0/85 (0) | – | – | 0/85 (0) |
| 26 | Terekhov | Dabigatran | 0/16 (0) | 0/16 (0) | 1/16 (6.25) | 0/16 (0) |
| 27 | Madan | Dabigatran | 0/47 (0) | 0/47 (0) | 0/47 (0) | 0/47 (0) |
| Total | – |
DOAC Warfarin |
38/9939 (0.38) 31/7168 (0.43) |
228/9769 (2.33) 136/7078 (1.92) |
386/9769 (3.95) 202/7078 (2.85) |
57/6906 (0.83) 31/5610 (0.55) |
DOAC, Direct Oral Anticoagulant.